Enhanced sublingual immunotherapy by TAT-fused recombinant allergen in a murine rhinitis model

Salari, Farhad; Vahedi, Fatemeh; Varasteh, Abdolreza; Ketabdar, Hanieh; Chamani, Jamshidkhan; Sankian, Mojtaba

doi:10.1016/j.intimp.2017.04.011

Cited by 6 publications

(6 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This finding correlated with Salari et al (2017) observing only a slightly altered protein structure of the fusion protein rTAT-Che a 3 compared to native Che a 3 protein. Moreover, no differences in Che a 3-specific IgG1-and, IgE levels and only slightly higher IgG2a levels were demonstrated in rTAT-Che a 3-immunized mice compared to animals only immunized with Che a 3 (Salari et al 2017).…”

Section: Pressupporting

confidence: 79%

“…The electrostatic interaction between the cationic TAT protein and the negatively charged cell membrane of eukaryotic cells can result in immune-modulating effects due to enhanced adherence and internalization (Salari et al 2017). The fusion protein rTAT-Che a 3 retained its immunogenic potential as shown by IgE reactivity with sera of allergic patients (Salari et al 2017). This finding correlated with Salari et al (2017) observing only a slightly altered protein structure of the fusion protein rTAT-Che a 3 compared to native Che a 3 protein.…”

Section: Presmentioning

confidence: 82%

“…HIV Trans-activating Regulatory Protein Salari et al (2017) investigated the sublingual immunotherapeutic potential of a recombinant HIV type 1 (HIV-1) trans-activating regulatory protein (TAT)-fusion protein with the main allergen of Chenopodium album pollen (Che a 3) in a murine rhinitis model (rTAT-Che a 3). The TAT protein transduction domain is a highly cationic 11-amino acid peptide derived from HIV-1 rich in arginine and lysine.…”

Section: Presmentioning

confidence: 99%

“…The TAT protein transduction domain is a highly cationic 11-amino acid peptide derived from HIV-1 rich in arginine and lysine. The electrostatic interaction between the cationic TAT protein and the negatively charged cell membrane of eukaryotic cells can result in immune-modulating effects due to enhanced adherence and internalization (Salari et al 2017). The fusion protein rTAT-Che a 3 retained its immunogenic potential as shown by IgE reactivity with sera of allergic patients (Salari et al 2017).…”

Section: Presmentioning

confidence: 99%

See 3 more Smart Citations

Adjuvant Allergen Fusion Proteins as Novel Tools for the Treatment of Type I Allergies

Blanco-Pérez

Papp

Goretzki

et al. 2019

Arch. Immunol. Ther. Exp.

View full text Add to dashboard Cite

While acute allergic symptoms can be managed by emergency medication, to date, allergen-specific immunotherapy (SIT) with allergen extracts is the only available curative treatment option. However, the risk of anaphylactic reactions, long treatment duration, varying extract quality, and underrepresentation of certain allergens currently prevent many patients from successfully undergoing SIT. Novel strategies are needed to enhance efficacy, safety, and convenience of allergy treatment. Fusion proteins combining allergen and adjuvant into a single molecule can efficiently induce immune responses by targeting the allergen to the relevant immune cells in vivo. Simultaneous co-delivery of both antigen and adjuvant to the same cell in a fixed molecular ratio triggers the uptake and presentation of the conjugated allergen in the context of the adjuvant-induced immune cell activation. This review summarizes the published strategies to improve the treatment of type I allergies using fusion proteins consisting of allergen (peptides) and either (1) immune-activating bacterial (flagellin, MPLA, S-layer, cholera-, and tetanus toxin), ( 2) viral (PreS, VP-1, TAT), or (3) fungal (FIP-fve) components, (4) immune-activating DNA motifs, (5) forced delivery of allergens to the MHC-II loading pathway, and (6) killing of immune cells expressing allergen-specific IgE by fusion of the allergen to diphtheria toxin.

show abstract

Section: Pressupporting

confidence: 79%

Section: Presmentioning

confidence: 82%

Section: Presmentioning

confidence: 99%

Section: Presmentioning

confidence: 99%

See 2 more Smart Citations

Adjuvant Allergen Fusion Proteins as Novel Tools for the Treatment of Type I Allergies

Blanco-Pérez

Papp

Goretzki

et al. 2019

Arch. Immunol. Ther. Exp.

View full text Add to dashboard Cite

show abstract

“…[7,102]. A TAT-fused recombinant allergen has been shown to enhance SLIT efficacy in murine models, potentially by promoting T reg -mediated immunomodulation [103].…”

Section: Recombinant Allergy Vaccinesmentioning

confidence: 99%

Impact of Allergen Immunotherapy in Allergic Asthma

et al. 2018

View full text Add to dashboard Cite

Although traditional pharmacological approaches improve outcomes in disease management for allergic asthma, these fail to modify the underlying immune responses. Allergen immunotherapy remains the only etiological therapy for the treatment of respiratory allergies for which clinical efficacy has been demonstrated through several well-controlled studies. In this review, we examine evidence from the past 5 years regarding the impact of allergen immunotherapy on allergic asthma to inform practitioners and stimulate further discussion and research.

show abstract

TGF-β1-stimulation of matrix metalloproteinase-13 expression by down-regulation of miR-203a-5p in rat osteoblasts

Saiganesh

Saathvika

Arumugam

et al. 2019

International Journal of Biological Macromolecules

View full text Add to dashboard Cite

Enhanced sublingual immunotherapy by TAT-fused recombinant allergen in a murine rhinitis model

Cited by 6 publications

References 38 publications

Adjuvant Allergen Fusion Proteins as Novel Tools for the Treatment of Type I Allergies

Adjuvant Allergen Fusion Proteins as Novel Tools for the Treatment of Type I Allergies

Impact of Allergen Immunotherapy in Allergic Asthma

TGF-β1-stimulation of matrix metalloproteinase-13 expression by down-regulation of miR-203a-5p in rat osteoblasts

Contact Info

Product

Resources

About